CompletedPhase 4

Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)

Denmark100 participantsStarted 2009-10

Plain-language summary

The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.

Who can participate

Age range18 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women who plan to undergo IVF or ICSI treatment * Woman's age \> 18 years but ≤ 35 years * Regular menstrual cycle (25-34 days) * BMI 18 to 30 inclusive * Signed patient information and informed consent forms Exclusion Criteria: * PCOS * More than 2 prior IVF/ICSI attempts * Diabetes mellitus, epilepsy, lever-, kidney-, heart- and metabolism disorders, according to the Investigator's assessment.

What they're measuring

The Oestradiol Concentration on the Day of Ovulation Induction

Timeframe: treatment day 10 to 14

Trial details

NCT IDNCT01339299

SponsorRegionshospitalet Viborg, Skive

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-07

Results submitted2013-09-25

View on ClinicalTrials.gov More Controlled Ovarian Stimulation trials